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Cross-presentation involves the presentation of peptides derived from internalized cargo
on major histocompatibility complex class I molecules by dendritic cells, a process critical
for tolerance and immunity. Detailed studies of the pathways mediating cross-presentation
have revealed that this process takes place in a specialized subcellular compartment with
a unique set of proteins. In this review, we focus on the recently appreciated role for
intracellular vesicular traffic, which serves to equip compartments such as endosomes
and phagosomes with the necessary apparatus for conducting the various steps of cross-
presentation. We also consider how these pathways may integrate with inflammatory
signals particularly from pattern recognition receptors that detect the presence of microbial
components during infection. We discuss the consequences of such signals on initiating
cross-presentation to stimulate adaptive CD8 T cell responses.
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INTRODUCTION
Classically, endogenous antigens such as proteins synthesized by
virally infected cells or tumor cells, are presented on major his-
tocompatibility class I (MHC I) molecules for detection by CD8
T cells. However, a seminal study by Bevan (1) showed that in
animals immunized with fully allogeneic cells, cytotoxic CD8 T
cell responses were seen specific for minor antigens from the
graft that were presented on MHC I molecules of the host (1).
This finding indicated that antigens from the transplanted cells
could be internalized by antigen presenting cells (APC) of the
host and presented on the host MHC I molecules. Bevan termed
the activation of CD8 T cells to this process of antigen trans-
fer as “cross-priming,” and later the actual process of antigen
transfer was called “cross-presentation” (2). A once poorly defined
phenomenon, cross-presentation is now considered to be a crit-
ical mechanism to mediate immune responses against infectious
agents and tumors as well as to induce peripheral tolerance (3).
The importance of cross-presentation becomes apparent given
the existence of several viruses that exhibit strict tissue tro-
pisms such as papilloma virus where infection is mainly con-
fined to epithelial cells in the skin barrier (4). Other examples
for viruses that do not infect APC include encephalomyocardi-
tis virus (EMCV) and semliki forest virus (SFV) (5). Addition-
ally, some viruses such as herpes simplex virus (HSV), measles,
retrovirus, canarypox virus, vaccinia virus, and lymphocytic chori-
omeningitis virus infect APC, but impair direct presentation of
antigen (6–13). Additionally, cross-presentation has been demon-
strated to play a critical role in mediating CD8 T cell immune
responses against parasitic infections such as Toxoplasma gondii
(14). Cross-priming has also been studied in the context of
bacterial infections such as Listeria monocytogenes and Mycobac-
terium tuberculosis. In these infections, host defense is primar-
ily mediated by dendritic cells (DC) that phagocytose infected
apoptotic cells and mediate cross-priming, thus allowing for
effective cytotoxic T lymphocytes (CTL) responses against the
pathogens (15–17). Hence, cross-presentation allows for a mech-
anism through which the antigen can be presented by the APC
without the need for direct infection.
Although other phagocytes have been reported to cross-present
antigen, DC are considered to be the primary cross-presenting cell.
The superior ability of DC to cross-present is largely attributed
to their antigen processing capacity. Endocytic pathways in DC
preserve and retain antigen epitopes via low lysosomal proteolysis
and expression of protease inhibitors (18). This aspect makes sense
when one considers that DC pick up antigen in the peripheral tis-
sue and migrate for several hours-days (12–24 h for dermal DC and
3 days for Langerhans cells) reaching the lymph nodes (19). Thus,
instead of being processed and degraded prematurely, retention
of antigen would allow optimal cross-presentation for subsequent
recognition by lymph node resident naïve CD8 T cells. However,
DC subsets are heterogeneous in their ability to cross-present
antigens. Subsets such as conventional splenic and lymph node
resident CD8α+ DC, migratory DC populations such as lung and
dermal CD103+ DC as well as monocyte-derived inflammatory
DC excel at cross-presentation (20–24). It is still unclear why these
DC subsets are specialized for cross-presentation. Interestingly,
conventional CD8α+ DC as well migratory CD103+ DC popula-
tions appear to rely exclusively on Batf3 and IRF8 transcription
factors for their development (25–28). Therefore, it is curious to
ask if the ability to cross-present is developmentally controlled by
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the Batf3/IRF8 transcription programs that enable these subsets to
have unique and specialized compartments geared toward cross-
presentation. On the other hand, in vitro studies argue that the
ability of splenic CD8α+ DC to cross-present antigen is induced
as a subsequent step in maturation aided by cytokines such as
granulocyte-macrophage colony-stimulating factor (GMCSF) or
exposure to microbial products (29).
Recent studies in human DC have proposed the lymphoid and
non-lymphoid resident BDCA3+ (CD141+) DC to be the human
counterparts of the cross-presenting murine lymphoid CD8α+
DC and non-lymphoid CD103+ DC (30–34). The BDCA3+ DC
subset is indeed an attractive candidate for the human homolog as
it shares with the murine CD8α+ and CD103+ DC several cell sur-
face markers, including DNGR1 and XCR1, transcription factors
such as Batf3 and IRF8, along with excelling at in vitro cross-
presentation assays. However, evidence also exists contradicting
the superiority of the BDCA3+ DC subset at cross-presentation
(35–37). Furthermore, patients harboring an autosomal domi-
nant mutation in IRF8 selectively lose BDCA-1+ DCs but not
BDCA3+ DCs in the peripheral blood, indicating that BDCA3+
DC is at least not developmentally regulated in the same manner
as murine cross-presenting subsets (38). Additionally although
Batf3 deficiency impairs development of BDCA3+ DC in vitro,
humanized mice reconstituted with Batf3 deficient progenitors
still display sufficient and comparable numbers of BDCA3+ DCs
(39). Thus, even though the human BDCA3+ DC subset appears
to be functionally related to the murine CD8α+ and CD103+ DC,
further studies are warranted to determine their developmental
program and subsequent specialization for cross-presentation.
Several groups have also focused their efforts on revealing
the intracellular pathways and molecular mechanisms mediating
cross-presentation at steady state. Three major mechanisms have
been determined. The phagosome-to-cytosol pathway involves
escape of the antigen into the cytosol, possibly mediated by
Sec61, followed by degradation by the proteasome and transport
of peptides into the endoplasmic reticulum (ER) by the trans-
porter associated with antigen presentation (TAP) to be loaded
onto MHC I molecules (40, 41). The ER-phagosome fusion path-
way involves fusion of the ER-Golgi intermediate compartment
(ERGIC) with the phagosome, leading to the formation of a so
called “ERgosome,” where ERGIC components such as TAP and
components of the peptide loading complex are recruited directly
to the phagosome. This recruitment is mediated through pair-
ing of the ER SNARE Sec22b with the plasma membrane SNARE
syntaxin-4, which is also found on phagosomes (42). In this model,
the antigen still requires escape into the cytosol for proteasomal
degradation and is then imported back to the “ERgosome” by TAP
to be loaded onto MHC I molecules (43, 44). In contrast to the
cytosolic pathways, the vacuolar pathway involves direct process-
ing of the antigen within the phagosome by endocytic proteases
such as cathepsins and subsequent loading of peptides onto MHC
I molecules (45).
Some of the above pathways suggest that cross-presentation
takes place in a specialized intracellular compartment. This com-
partment could be endosomes or phagosomes depending on the
size of the exogenous antigen and mode of internalization. For
instance, in the ERgosome model, cross-presentation takes place
in a subcellular compartment bearing characteristics of both the
ERGIC and the endosome/phagosome. In this review, we elaborate
on the vesicular pathways that serve to bring various components
of the cross-presentation machinery to such specialized intra-
cellular compartments. We discuss the unique combination of
proteins in these compartments that make it attractive for cross-
presentation at steady state and how this compartment might be
modified and further optimized for efficient cross-presentation in
the scenario of infection. We also review evidence for regulation
of cross-presentation during microbial stimulation and discuss if
this process can still take place at steady state.
NATURE OF THE CROSS-PRESENTING COMPARTMENT AT
STEADY STATE
In recent years, several groups have elucidated the architecture
of the “cross-presenting” compartment at steady state. This com-
partment contains several identified proteins brought in by dis-
tinct vesicular pathways. These proteins may all be present in
the compartment. Alternatively, these vesicular pathways may be
mutually exclusive of one another, culminating in the presence
of only some of these identified proteins. Regardless, these pro-
teins serve as important players in executing different steps of the
cross-presentation response (Figure 1).
MAINTENANCE OF OPTIMAL ALKALINE pH
As antigens are internalized by endocytosis or phagocytosis, they
undergo gradual proteolytic degradation along their journey from
early endosomes and phagosomes to lysosomes (Figure 1A). Once
in lysosomes, antigens are degraded by lysosomal proteases, which
could destroy potential peptide epitopes crucial for T cell activa-
tion. DC circumvent this problem by expressing low levels of lyso-
somal proteases (18). Additionally, since most of these proteases
function optimally at acidic pH (46), maintenance of a strongly
alkaline pH in the cross-presentation compartment would inhibit
protease activity, thus preventing overt and premature degradation
of antigens. To this end, DC were reported to have high phago-
somal pH, reaching values of 7.5–8 in contrast to macrophages
which rapidly acidified their phagosomes, reaching values of 4.5–
5 following phagocytosis of inert latex beads (47). Alkalinization
of phagosomes in DC was attributed to selective recruitment,
assembly and functioning of nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase NOX2. Finally, NOX2 activity was
shown to be crucial for cross-presentation as genetic deletion of
NOX2 subunit gp91phox led to abrogation of cross-presentation.
How does NOX2 reach the cross-presenting compartment?
Recruitment of NOX2 is facilitated by Rab27a (48), a small guano-
sine tri-phosphatase (GTPase), which was initially characterized to
mediate regulatory exocytosis of secretory vesicles in hematopoi-
etic and non-hematopoietic cells (49). In a separate study, the
Rac2 GTPase was demonstrated to also control the recruitment
and assembly of phagosomal NOX2 in splenic CD8α+ DC as well
as in in vitro derived bone-marrow derived DC (50). Additionally,
VAMP-8, a SNARE protein which interacts with plasma membrane
and phagosomal SNAREs syntaxin-4 and SNAP-23 (51), has also
been recently reported to play a role in NOX2 recruitment and
in mediating cross-presentation of phagocytic antigen (52). Inter-
estingly, the protozoan Leishmania specifically cleaves VAMP-8
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FIGURE 1 |The cross-presentation compartment at steady state. Several
vesicular pathways have been proposed to mediate delivery of key proteins
that play an integral role in the crucial steps of cross-presentation including
maintenance of alkaline pH (A), processing of antigen to peptides (B) and
subsequent loading of peptides onto MHC I molecules (C). (A) Delivery of
NOX2 via Rab27a, VAMP-8, and Rac2 is critical for maintaining an alkaline pH
in intracellular cross-presenting compartments. Alternatively, recruitment of
ERGIC via Sec22b also regulates pH and proteolytic activity in phagosomes.
The ERGIC may contain protease inhibitors such as Cystatin C and lipid bodies
(LB) that could directly alter phagosomal pH and enzymatic activity of
proteases. (B) In the vacuolar pathway, antigen is directly processed into
peptides by phagosome resident proteases such as cathepsins. In the
cytosolic pathway, the antigen may need to be first unfolded by GILT prior to
exit into the cytosol via a channel. This mystery translocon may be Sec61 and
could be present in ERGIC, thereby recruited to the cross-presenting
compartment via Sec22b. Once in the cytosol, antigen is then degraded into
peptides and shuttled back into the phagosome via phagosomal TAP. TAP is
dependent on Sec22b for its recruitment from ERGIC to endocytic
compartments. Finally, IRAP, which is present on Rab14+ and Syntaxin 6+
endosomes, is recruited to phagosomes and mediates trimming of imported
peptides that are further optimized for cross-presentation. (C) Lastly,
processed and trimmed peptides have to now be loaded onto MHC I
molecules. Source of MHC I in such compartments is unclear and could
either be recruited from (1) ERGIC via Sec22b or (2) recycling from plasma
membrane or (3) recruitment from endolysosomal compartments via CD74. In
all cases, the peptide loading complex (PLC) is recruited from ERGIC via
Sec22b to the compartment and can chaperone loading of exogenous foreign
peptides to create “cross-presentable” peptide-MHC complexes.
in phagocytes to prevent NOX2 assembly, thereby acidifying the
phagosomes, in order to evade the cross-presentation response.
However, it is still unclear if these GTPases and SNARE proteins
act in concert or independently of one another to mediate recruit-
ment of NOX2 and in turn to control cross-presentation. Given
that VAMP-8 also participates in trafficking of secretory vesicles
(53, 54), it is tempting to speculate that VAMP-8 and Rab27a
might be present in similar secretory granules and are routed to
the cross-presenting compartment upon entry of antigen.
In a second pathway, Sec22b mediated recruitment of ERGIC
components has additionally been implicated in the maintenance
of an alkaline pH (42). Sec22b silenced DC phagosomes have
higher levels of mature cathepsin D, increased proteolytic activ-
ity, leading to accelerated degradation of antigen. These results
therefore suggest that the ERGIC contains protease inhibitors.
Which protease inhibitors could be involved? The cystatin family
of protease inhibitors has been implicated to play a role in antigen
presentation. Cystatin C was demonstrated to inhibit degrada-
tion of CD74, leading to enhanced accumulation of MHC II in
endolysosomal compartments (31). Interestingly, cystatin C is
abundantly expressed by CD8α+ DC compared to CD8α− DC
from the spleen (32), and only partially colocalizes with endolyso-
somal compartments (31, 32). Given that the cellular localization
of cystatin C as well as its role in cross-presentation is still unclear,
a feasible possibility is that cystatin C could perhaps colocalize
with ERGIC and play a role in cross-presentation.
Another explanation for why recruitment of ERGIC would
delay phagosome maturation is that the ERGIC may contain lipid
bodies (LB) that have been implicated in regulating phagosomal
alkalinization and antigen cross-presentation (55). These LB accu-
mulate in the cytosol and on DC phagosomes in an interferon
(IFN)-inducible ER-resident GTPase (Igtp) dependent manner.
Specifically, Igtp was shown to interact with LB resident adipose
differentiation related protein (ADFP) to mediate formation of
LB, which were crucial for cross-presentation (55).
ANTIGEN PROCESSING
The cytosolic pathway model of cross-presentation stipulates that
once antigen is internalized, it has to make its way out of the
endosome/phagosome and into the cytosol for proteasomal degra-
dation (Figure 1B). It is generally thought that prior to export
into the cytosol, antigens may need to be unfolded. For certain
antigens, this is a challenge owing to specific di-sulfide bonds
holding the structure of the antigen together. In this case, gamma-
interferon-inducible lysosomal thiolreductase (GILT) has been
shown to be critical for cross-presentation of di-sulfide bonds
containing antigen derived from HSV infected cells (56). Once
unfolded, antigen is then routed to the cytosol through a channel,
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the identity of which still remains enigmatic and controversial.
Sec61, a translocon involved in the ER associated degradation
pathway (ERAD) was regarded as a top candidate given that
blocking Sec61 activity by using Pseudomonas aeruginosa bacteria
exotoxin A resulted in loss of cross-presentation of soluble OVA
antigen (41). However, the evidence for exotoxin A directly and
solely blocking Sec61 channel activity is still lacking. Interestingly,
DC lacking Sec22b SNARE protein via short hairpin ribonucleic
acid (shRNA) targeted deletion, showed impaired antigen export
from endocytic compartments, thus arguing for the recruitment
of an ERGIC resident translocon channel (42). Further studies
analyzing phagosomal proteomics of these Sec22b sufficient and
deficient DC would be integral to revealing the identity of the
enigmatic translocon.
Once in the cytosol, it is well accepted that the antigen under-
goes proteasomal degradation resulting in the generation of
peptides. These peptides are then reimported by TAP into the
lumen of the cross-presenting compartment (57). TAP is an ER
and ERGIC resident protein that has been demonstrated to be
recruited to phagosomes in a Sec22b dependent manner (42). Sev-
eral groups have confirmed the dependence of cross-presentation
on TAP, although in the case of certain bacterial antigens, cross-
presentation can take place even in the absence of TAP via the
vacuolar pathway where antigens are processed within endosomes
and phagosomes by resident proteases (3).
Upon internalization of exogenous antigens, newly gener-
ated peptides can be trimmed by endosomal insulin-regulated
aminopeptidase (IRAP) to be further optimized for cross-
presentation (58). IRAP−/− DC are impaired in their ability to
cross-present soluble and particulate antigen, thus implicating
the importance of IRAP in cross-presentation. IRAP colocalizes
with Rab14+ and syntaxin 6+ endosomes at steady state, and is
recruited to phagosomes after antigen uptake (58, 59). Whether
IRAP depends on Rab14 GTPase and syntaxin 6 SNARE proteins
for its delivery to the phagosomes remains to be studied.
PEPTIDE LOADING ON MHC I
Processed and trimmed peptides are now faced with the possibil-
ity of being loaded on MHC I molecules that are present within
endosomes and phagosomes (Figure 1C). A question that remains
is where these MHC I molecules are recruited from. An attractive
possibility is that MHC I molecules are present in the ERGIC and
that perhaps Sec22b can deliver MHC I along with its chaperone
proteins such as calreticulin and tapasin to the cross-presenting
compartment. However, analysis of MHC I molecules in cell
lines has revealed that MHC I molecules are transiently trafficked
through the ERGIC at steady state. In fact, MHC I accumulated in
ERGIC only in conditions where these molecules are not bound to
high affinity peptides which could occur in the absence of TAP or
calreticulin or when traffic out of the ERGIC is blocked (60–64).
Whether MHC I trafficking in APC occurs similarly is still unclear.
An alternative possibility is that MHC I may be derived from the
plasma membrane. Indeed, endocytosis and subsequent recycling
of MHC I has been extensively documented in several cell lines
where internalized MHC I are delivered to endosomal recycling
compartments (ERC) in a step prior to being re-routed to the
plasma membrane (63). Trafficking patterns of MHC I in APC are
less clear. Some studies in APC confirm the reliance on plasma
membrane derived MHC I, where internalization of surface MHC
I molecules was shown to be dependent on a conserved tyrosine
within the cytosolic domain of the MHC I, and to a lesser extent
on a conserved serine phosphorylation site (65, 66). Mutations in
these conserved sites resulted in inhibition of cross-presentation
both in vitro and in vivo. However, given the strong evidence in
cell lines for accumulation of MHC I in ERC, further studies are
warranted to determine the contribution of MHC I molecules
recycling through the ERC to cross-presentation.
Finally, it was also recently shown that CD74, which was orig-
inally characterized to route MHC II molecules from the ER to
lysosomal compartments (67), was also important in mediating
cross-presentation of viral and cell-associated antigen (68). CD74
was found in complex with immature endoglycosidase sensitive
MHC I, indicating that it associates with newly synthesized MHC
I in the ER (69). In CD74−/− DC, MHC I molecules were present
to a lesser extent in LAMP-1+ compartments, implying that CD74
delivers MHC I from the ER to endolysosomal compartments.
NATURE OF THE CROSS-PRESENTING COMPARTMENT
DURING INFECTION
In spite of these studies detailing the molecular and cellular
makeup of cross-presenting compartments at steady state, the
mechanisms underlying regulation and remodeling of this com-
partment during infection remain largely undefined. Upon uptake
of microbial or infected cellular cargo, the phagosomal or endoso-
mal compartment can be substantially modified by the acquisition
of pattern recognition receptors (PRRs) (16). PRRs are evolu-
tionarily conserved receptors that recognize and respond to con-
served pathogen-associated molecular patterns (PAMPs) which
are unique to microbes (70). Upon PRR engagement, intracellular
signal transduction pathways are initiated such as those mediated
by nuclear factor-κB (NF-κB), mitogen-activated protein kinases
(MAPKs), and IFN-regulatory factors (IRFs) (71). These path-
ways are critical for providing immunity against several pathogen
infections.
Several families of mammalian PRRs have been identified,
namely Toll-like receptors (TLRs), nucleotide-binding oligomer-
ization domain-like (NOD-like) receptors (NLRs), RIG-I like
receptors (RLRs), and C-type lectin receptors (CLRs) (72). Indeed,
TLRs were the first family of PRRs to be studied in detail (73–
75). We focus here on recent developments in the biology of TLR
that enable the recruitment of these receptors and assembly of
their signaling machinery. This recruitment aids in the transduc-
tion of responses from the compartment itself, allowing localized
phagosomal or endosomal specific control of responses, including
presentation of exogenous antigen on MHC I and MHC II mol-
ecules. To signal and regulate presentation of exogenous antigen
from endosomal compartments, TLRs first need to be recruited to
the relevant compartment.
TLR4
TLR4 is a plasma membrane resident “surface” TLR that can
be endocytosed and also signal from intracellular compartments
upon interaction with its ligand lipopolysaccharide (LPS).
TLR4 initially engages toll-interleukin 1 receptor (TIR)
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domain-containing adaptor protein (TIRAP) and myeloid dif-
ferentiation primary-response protein (MyD88) to initiate sig-
nal transduction from the plasma membrane (76). Subse-
quently, TLR4 is internalized into endocytic compartments
and engages TRIF-related adaptor molecule (TRAM) and TIR-
domain-containing adaptor inducing IFN-β (TRIF) (76). In
fact, blocking TLR4 endocytosis using dynamin inhibitors selec-
tively inhibits TRIF-TRAM mediated IRF3 dependent type I IFN
responses without affecting TIRAP-MyD88 dependent signal-
ing (77).
Recently, CD14 was shown to regulate the endocytosis of TLR4
from the plasma membrane during stimulation with LPS (78).
TLR4 acts as a cargo for CD14, which transports the receptor and
LPS to endosomes in a Syk and PLCγ2 dependent process where
TRIF signaling leads to IFN-β production. While CD14 is critical
for TLR4 endocytosis and IFN-β production in response to soluble
LPS, TLR4 endocytosis in DC can proceed in the absence of CD14
during phagocytosis of E. coli or LPS-coated beads, although a
lower percent of TLR4 is internalized compared to soluble LPS.
Notably, despite lower percent TLR4 internalization in response
to these particles, IFN-β production, which relies on TLR4 signal-
ing from endocytic compartments, was unaffected in the absence
of CD14. This result suggests that in the case of phagocytosed
cargo, TLR4 can accumulate on phagosomes from another source
independently of the plasma membrane.
Indeed, the small GTPase Rab11a was shown to play a cru-
cial role in trafficking TLR4 from ERC to phagosomes containing
gram-negative and not gram-positive bacteria, leading to IRF3
activation and IFN-β transcription (79). Additionally, adaptor
protein 3 (AP-3) also plays a role in recruiting TLR4 and MyD88
from intracellular stores to phagosomes containing TLR4 lig-
ands (80). Interestingly, AP-3 dependent recruitment of TLR4 and
MyD88 was crucial for mediating production of pro-inflammatory
cytokines selectively in response to phagocytic cargo and not to
soluble LPS. Hence, the mode of uptake can dictate the pathway
of delivery of TLR4.
It is curious to ask if the recruitment of TLR4 via these regu-
latory transport proteins contributes toward antigen presentation
and adaptive immunity. For MHC II presentation, phagosome
autonomous TLR4 signaling led to accelerated phagosome matu-
ration and subsequent degradation of CD74 specifically in phago-
somes bearing TLR ligands and not other phagosomes in the
same DC (81, 82). Additionally, impaired recruitment of TLR4
to phagosomes in AP-3 deficient mice also led to decreased MHC
II presentation (80). However, whether any of these proteins reg-
ulate cross-presentation of antigen internalized via endocytosis or
phagocytosis remains to be investigated.
TLR9
TLR9 is an endosomal receptor and begins its journey in the ER,
where it associates with the chaperone protein Unc-93 homolog
B (UNC93B), which mediates its transport to endosomes (83).
Recently, recruitment of TLR9 and UNC93B was demonstrated
selectively to phagosomes that contained DNA and anti-DNA
immunoglobulin (Ig) complexes (84). Importantly, phagosomal
TLR9 recruitment did not depend on its ability to sense the pres-
ence of TLR9 ligand DNA but instead relied on Fc receptor γ
(FcRγ) mediated engagement by Ig complexes. These data sug-
gest that Ig mediated FcRγ signaling leads to recruitment of
TLR9 to phagosomes. When these phagosomes also contain the
TLR9 ligand DNA, TLR9 signaling is engaged, resulting in IFN-α
secretion. Given that engagement of FcRγ prepares phagosomes
for optimal TLR9 signaling, it is tempting to speculate that this
synergy between FcRγ and TLR9 may also impact subsequent
cross-presentation responses of antigen complexed with DNA-Ig
aggregates.
TLR2
TLR2 is a cell surface TLR that synergizes with other surface TLRs
such as TLR1 and TLR6 to mediate MyD88 dependent signal trans-
duction responses. Similar to TLR4, there are reports showing
TLR2 localization to endosomal compartments specifically early
endosomes, lysosomes, and Rab11a+ vesicles in monocytes (85).
Some studies also indicate TLR2 dependent induction of type I
IFN signaling from endocytic compartments (86, 87). How TLR2
is directed to such compartments is still unclear.
PRR REGULATION OF CROSS-PRESENTATION
Studies looking at the role of PRRs in cross-presentation have
been largely limited to TLRs and CLRs. These receptors are well
suited to regulate cross-presentation as they are present at the
plasma membrane as well as along the endocytic pathway, where
they encounter microbial antigen and initiate signaling to regulate
adaptive immune responses such as cross-presentation. Here, we
present evidence supporting regulation by these receptors.
TOLL-LIKE RECEPTORS
There are several studies that show that TLR signaling enhances
cross-priming of CD8 T cells (88). The in vivo contribution
of TLR3 to cross-priming became clear after an elegant study
demonstrated that signaling via TLR3 leads to maturation of DC
and therefore promotes virus-specific CD8 T cell responses (5).
Another study showed that injecting mice with apoptotic vesi-
cles derived from M. tuberculosis infected macrophages, activates
DC via TLR2 in a MyD88 dependent manner and can cross-prime
CD8 T cells, thereby protecting mice from developing tuberculosis
infection (17). Moreover, by employing biodegradable micros-
pheres for the delivery of phagocytic cargo to DC, Schlosser et al.
were able to demonstrate that the presence of both TLR ligand
and antigen within the same phagosome yielded efficient CTL
responses as compared to when the ligand and antigen are located
in separate phagosomes (89).
One caveat of the studies above is the inability to distinguish
the effects of TLR signaling on cross-presentation versus cross-
priming. For example, a couple of studies revealed that TLR3 and
TLR9 ligands could both induce cross-presentation of OVA by DC
(90, 91). This induction of cross-presentation was found to be
dependent on TLR signaling as DC from Tlr9−/− and Myd88−/−
mice were unable to cross-present antigen after exposure to TLR
ligands. However, the authors of these studies relied exclusively
on T cell activation as a measure of displayed peptide-MHC I
complexes. Given that TLR signaling also controls DC maturation
and expression of co-stimulatory molecules that are pivotal for T
cell activation, it is difficult to rule out the confounding factor of
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impaired co-stimulation and decreased DC maturation seen with
TLR deficient DC. In fact, the inability of Myd88−/− DC to acti-
vate CD8 T cells after phagocytosis of virally infected cells was
fully restored by treatment with a CD40 cross-linking antibody
suggesting that defective cross-priming was due to impaired TLR
induced co-stimulation rather than cross-presentation per se in
this particular case (92).
The most direct way to assess cross-presentation is to use
a conformation dependent antibody directly against preformed
peptide-MHC I complexes on the surface of the APC. However,
these antibodies are quite insensitive and work successfully only
when DC were pulsed with large amounts of antigen. Neverthe-
less, Christian Kurts’ group successfully used 25D1.16 antibody
to detect SIINFEKL-MHC I complexes and thus demonstrated
increased cross-presentation with TLR signaling after uptake of
soluble OVA in the presence of LPS (93). This increase in cross-
presentation was mediated by TLR4, MyD88 and not TRIF signal-
ing. However, this study was focused on the cross-presentation of
soluble antigen and hence whether TLR signaling enhances cross-
presentation of phagocytosed particulate antigen remains to be
determined.
C-TYPE LECTIN RECEPTORS
C-type lectin receptors contain at least one carbohydrate recog-
nition domain via which they bind to sugar moieties on self or
microbial derived antigens. CLRs can regulate cross-presentation,
although most of them do so by regulating antigen uptake. For
example, CD209 and mannose receptor have been reported to
increase internalization of cargo and target antigens to early
endosomes for cross-presentation (94, 95). DNGR1 was also
reported to enhance cross-presentation of cellular antigens derived
from necrotic dying cells (96). Interestingly, despite intact mat-
uration phenotypes and maintenance of signals to relay co-
stimulation in DNGR1 deficient DC, these DC were impaired
in cross-presentation, suggesting specific regulation of cross-
presentation rather than cross-priming (97). DNGR1 is also
expressed at high levels in subsets of DC specialized for cross-
presentation including murine CD8α+ DCs and tissue-resident
CD103+ CD11b− DCs as well as in human counterparts BDCA3+
DC (39).
CAN CROSS-PRESENTATION STILL TAKE PLACE AT STEADY
STATE?
In the absence of inflammation or infection, cross-presentation of
self-antigens at steady state can take place, leading to tolerance to
host antigens and deletion of potentially auto-reactive CD8 T cells.
Indeed, generation and activity of CTL must be tightly controlled
to avoid auto-reactivity to self, given the potency of CTL in killing
infected target host cells (98, 99). Here, we review existing evidence
for the role of cross-presentation in both central and peripheral
tolerance mechanisms.
PERIPHERAL TOLERANCE
Peripheral tolerance constitutes mechanisms of tolerance that
take place after mature lymphocytes enter into the periphery.
There are several studies that argue for the constitutive TLR or
PRR-independent nature of cross-presentation for the induction
of peripheral cross-tolerance to non-inflammatory self-antigens,
leading to deletion of self-reactive CTL. Many of these models
employed the expression of neo-self-antigens under the control
of tissue-specific promoters like the rat insulin promoter (RIP).
These models ensure that the antigens are expressed outside of
the thymus, allowing researchers to specifically study peripheral
tolerance.
Cross-tolerance was first demonstrated when OVA specific
OT-I CD8 T cells were efficiently deleted after being adoptively
transferred into a mouse expressing OVA under control of the
RIP (RIP-mOVA) (100). Cross-tolerance was also shown to be
important for the control of endogenous auto-reactive CD8 T
cells specific for naturally expressed self-antigen (101). In this
study, the authors bred the RIP-mOVA mice with mice lacking
GTPase Rac1 in CD11c+ cells to generate Rac1-RIP mice. Conve-
niently, deficiency in Rac1 GTPase selectively affected the ability
of CD8α+ DC to internalize antigen (33), resulting in impaired
cross-presentation while leaving the classical MHC II and MHC I
pathways of antigen presentation unaffected (101). Consequently,
they were able to demonstrate that DC in Rac1-RIP mice failed
to cross-present transgenic self-antigen and hence failed to delete
transferred OT-I T cells. Moreover these mice developed symp-
toms of diabetes. Interestingly, mice that just had Rac1 deleted
in CD11c+ cells also had higher numbers of endogenous CD8
T cells, although the mice seemed healthy and did not develop
autoimmunity. However, when CD25 depleted T cells from these
mice were transferred into lymphopenic hosts, the hosts devel-
oped several signs of autoimmunity as a result of homeostatic T
cell proliferation. Hence, the above studies clearly demonstrate the
role of cross-presentation under steady state to induce peripheral
tolerance.
An interesting study by Christian Kurts’ group looked to see
if tolerogenic DC could be converted into autoimmunogenic DC
after exposure to stimulating conditions such as TLR ligands (102).
TLR ligands were able to induce CTL mediated autoimmunity only
in cases where antigen specific CD4 T cell help was provided con-
comitantly. These results demonstrated that the mere presence of
TLR ligands, such as those present in commensal bacteria or those
derived from the use of vaccine adjuvants, is not sufficient to break
cross-tolerance mechanisms.
CENTRAL TOLERANCE
In addition to peripheral tolerance, cross-presentation was also
implicated in the induction of central tolerance (103). Cen-
tral tolerance is induced in the thymus where developing thy-
mocytes that recognize peptide-MHC complexes are positively
selected to express either CD4 or CD8 molecules. Subsequently,
thymocytes that are able to recognize self-peptide-MHC com-
plexes with high affinity are efficiently deleted via negative selec-
tion. Medullary thymic epithelial cells (mTECs) and DC play a
critical role in mediating negative selection. mTECs exclusively
express a broad range of tissue-specific antigens (TSA) (104,
105). In spite of expressing both MHC II and MHC I molecules,
mTECs are poor APC. Bevan’s group was the first to show that
bone-marrow derived cells in the thymus were capable of cross-
presenting antigen captured from mTECs (103). However, this
study also showed that mTECs, by themselves, were capable of
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direct presentation on MHC I molecules and were sufficient to
induce CD8 T cell deletion, thus diminishing the importance of
cross-presentation in central tolerance. A recent report does point
to the relevance of cross-presentation by human thymic DC. Upon
analyzing peptides eluted from both MHC I and MHC II mole-
cules of human thymic DC, the authors observed that around
22% of the MHC I ligands were derived from proteins present
in the vesicular/extracellular compartment the presentation of
which would typically be associated with the classical MHC II
pathway (30).
CONCLUSION
The studies we reviewed here certainly point to the constitu-
tive nature of cross-presentation, however, an increasingly large
body of work now provides strong evidence for the capacity to
enhance cross-presentation by signals from inflammatory PRRs.
Having mechanisms of regulation in place allows for the genera-
tion of robust CTL responses during an infection while maintain-
ing induction of tolerance at steady state. Further insight into
these regulatory mechanisms may potentially help in tailoring
better therapeutic strategies to combat infectious agents as well
as tumors, while preventing autoimmunity. Hence, elucidating
the mechanistic differences in vesicular trafficking between steady
state and inflammatory cross-presentation would be important
for developing new rationales in the design of safe and effec-
tive vaccines for anti-viral, anti-bacterial as well as anti-tumor
immunity.
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